RE: patent worth multi million dollars4 Feb 2022 10:24
Overview of LY RAMID Limited
Licence holder of the largest global IP portfolio on Midkine
Patent portfolio covering composition of matter and method of use
of Midkine inhibitors
Novel disease target
Potential to exploit the broad therapeutic potential of Midkine for aa
number of clinical indications of unmet needs
Developing first in class oligonucleotide drugs
IP provides a platform to develop first-in-class drugs for the
treatment of COVID-19 patients, cancer, autoimmune disorders
and chronic kidney disease
Extensive validation by LYRAMID
Therapeutic potential of Midkine blocking drugs validated during
more than 10 years of research including collaborations with
leading academic centres and clinicians resulting in over 1,000
scientific publications
Headquartered in Australia
Collaborations with leading Medical Research Institutes
42.5% R&D cash rebate for Australian and overseas activities
World-wide collaborations
Supports IP portfolio research with reduced cost to Lyramid
Adds diversity of people and research into different disease targets